SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AspenBio Pharma, Inc.
Reporting Date: July 19, 2011
Business Context: The registrant is a biopharmaceutical company based in Castle Rock, Colorado. This filing reports a corporate event regarding the advancement of its AppyScore™ pre-pivotal clinical trial.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific operational event and does not contain financial statements or quantitative financial data.
Material Changes
Item 8.01 Other Events: On July 19, 2011, the Company issued a press release announcing that the AppyScore™ pre-pivotal trial is advancing with patient enrollment ongoing at seven hospitals. No financial material changes were reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the progress of the AppyScore™ trial. The document does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the announcement of the trial's status.
Key Facts for Investor Verification
- Verify the details of the AppyScore™ pre-pivotal trial progress in the attached press release (Exhibit 99.1).
- Confirm the number of hospitals currently enrolling patients (stated as seven in the filing).
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.
- Ensure the registrant name is AspenBio Pharma, Inc., not Riot Platforms, Inc. (as indicated in the request metadata).